SARS-CoV 2
Conditions
Keywords
MALDI-TOF MS
Brief summary
Since March 2020, SARS-CoV2 virus (nCoV19; COVID-19) is considered pandemic. Its high rate of spread and infection in the human population and the lack of effective and validated treatment have led the authorities of several countries to confine their populations to slow the spread of COVID-19. As part of the management of this health crisis, the screening of individuals is essential in order to isolate infected cases. These screening tests are currently performed on nasopharyngeal swabs using RT-PCR for the detection of viral RNA. Although sensitive and specific, these tests remain relatively long (2-5 hours), expensive and the strong international demand for nucleic extraction kits and enzymes are factors limiting the implementation of widespread screening (problem of supply of swabs, molecular biology consumables). In order to prevent the risks of a shortage of screening means, we propose to develop an innovative alternative strategy, PCR-free, based on the detection of specific protein signatures in human saliva by MALDI-TOF MS profiling. MALDI-TOF MS profiling is a method used in routine diagnostics by microbiology laboratories for the identification of microorganisms. MALDI-TOF MS profiling has been successfully used to classify individuals according to their infectious status (oral pathologies) based on the analysis of their saliva, but also as a tool for the identification of respiratory viruses from cell culture supernatants. In addition, we have expertise and skills in the field of MALDI-TOF MS profiling and have implemented new strategies to improve the quality of profiles and their analysis, particularly in the context of entomological and vector identification projects. Finally, recent Chinese studies have reported that COVID-19 was detectable in saliva by RT-PCR. The main objective of this study is to develop a test based on the MALDI-TOF profiling method to detect individuals infected with SARS-CoV2 from saliva sample.
Interventions
BIOLOGICALSaliva collection
Saliva samples are regularly collected over a period of up to 30 consecutive days.
OTHERClinical assessment
The participant's clinical data will be collected regularly over a period of up to 30 consecutive days.
Sponsors
Direction Centrale du Service de Santé des Armées
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
* 18 years of age; * screened for SARS-CoV2 by RT-PCR from a nasopharyngeal swab within 96 hours prior to inclusion.
Exclusion criteria
* Patient admitted to intensive care; * Pregnant woman.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Development of a test based on the MALDI-TOF profiling method to detect individuals infected with SARS-CoV2 from saliva sample. | Day 30 | The development of this test is based on machine learning techniques, which involve training a mathematical model, in which the results of the mass spectrometry analysis of saliva samples and clinical data will be used to determine the information needed to distinguish a saliva sample from a SARS-CoV2-infected participant from a healthy saliva sample. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Rate of correct classification by the test (MALDI-TOF MS profiling) from saliva sample | Day 30 | For each saliva sample, the status (correct or incorrect) of the classification of the sample (infected or not infected) by the test (MALDI-TOF MS profiling) will be determined. Then the rate of correct classification will be calculated. The test will be considered efficient when it has reached a correct classification rate of more than 95%. |
| Rate of correct classification by RT-PCR from saliva sample | Day 30 | For each saliva sample, the status (correct or incorrect) of the classification of the sample (infected or not infected) by RT-PCR will be determined. Then the rate of correct classification by RT-PCR will be calculated. |
| Identification of proteins specific to the SARS-CoV2 infection | Day 30 | On each saliva sample, the expression of proteins will be determined using mass spectrometry. By comparison between SARS-CoV2 infected saliva samples and non-infected saliva samples, the presence of proteins that are specifically expressed in SARS-CoV2 infected saliva samples will be determined. |
| Presence of a positive anti-SARS-CoV2 antibody response by RT-PCR | Day 30 | On each SARS-CoV2 infected saliva sample, the presence of anti-SARS-CoV2 antibodies, by RT-PCR, will be determined. |
| Correlation between the identified protein markers and the clinical course of the participants. | Day 30 | In SARS-CoV2 infected participants (Covid+ hospitalization group and Covid+ outpatient group), the presence of a correlation between the presence of proteins specific to the SARS-CoV2 infection and the clinical evolution of patients will be determined. |
Countries
France
Outcome results
None listed